Daunorubicin

This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZS7284E0ZP, chemically known as 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)- but generally known as daunorubicin, which bears US NIH Compound Identifier 30323. European Medicines Agency schedules Daunorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06917MIG. The term DAUNORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules daunorubicin in its Anatomical Therapeutic Chemical (ATC) Classification. DAUNORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule daunorubicin under HS 29419000 and SITC 54139. As of Q4 2014, DAUNORUBICIN remains the US FDA Preferred Term for this commodity. Daunorubicin bears US NLM identifiers UMLS ID C0011015 and NCI Concept Code C62091. SMILES: O(C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)C)C1OC(C(O)C(N)C1)C.